After struggling to make recommendations about the product, an FDA panel rejects Hemispherx...

|About: Hemispherx Biopharma, Inc (HEB)|By:, SA News Editor

After struggling to make recommendations about the product, an FDA panel rejects Hemispherx Biopharma's (HEB) chronic fatigue syndrome treatment Ampligen, saying it isn't ready for marketing. Several panel members struggled with their decisions because it appears the drug works in certain patients even if it wasn't strongly shown in the clinical data presented to the panel. Shares -20% AH.